The global joint pain injections market is anticipated to grow at a CAGR of around 8.2% during the forecast period 2021 to 2028 and to reach around US$ 10.3 Bn by 2028.
An increase in the number of patients in hospitals related to arthritis and increasing demand for enhanced pain management solutions are major factors expected to drive the growth of global joint pain injections market. In addition, rapid technological advancements in healthcare sector, increasing government focus on patient care, coupled with increasing consumer spending on healthcare care are factors expected to augment the growth of joint pain injections market. Arthritis is growing among adults and children’s resulting in demand for pain management drugs and injections. Country such as the US is witnessing peak in the case related to arthritis. According to US Arthritis Foundation, arthritis or rheumatic disease cases were increasing among consumers there were 54,000,000 in adults and 0.3 Million in babies & children. Osteoarthritis is the most common arthritis that affects people. In the US about 31 million people are affected by osteoarthritis. According to the survey, the prevalence of symptomatic knee OA is approximately 10% in men and 13% in women. In 2010, more than 719,000 total knee arthroplasties were performed in the US.
To learn more about this report, request a free sample copy
Increasing cases of joint pain in developed & developing countries and rapid development of injections that allow the doctor to assess the root causes of pain can also help to alleviate pain quickly is expected to impact the growth of joint pain injections market. The injections given on the facet joint are filled partially with an anesthetic agent that makes the muscles, ligaments, and articular capsules numb. The increased demand for non-surgical care has been recognized as a vital factor in driving the production during the forecast period of facet joint injections. In addition, it is also expected to contribute significantly to the overall build-up of the facet joint injection in the appraisal period to improve the focus on effective pain relief. Major players approach towards enhancing the business through strategic mergers & acquisitions and new product launches is expected to boost the global market growth. In 2017, Bioventus, a global medical service provider received US FDA approval for its knee osteoarthritis pain injection "Durolane”.
The product is a single-injection hyaluronic acid product that has been a proven OA knee pain reliever for patients for more than 15 years. Factors such as stringent government regulations related to product approval and high cost of treatment along with the product are factors expected to hamper the growth of global joint pain injections market. In 2017, Sanofi Genzyme, a biotechnology company had to initiate a voluntary product recall for one lot of “Synvisc-One”, a brand of hyaluronic acid. The lot was found with the contamination that increased the side effects of the medication. In 2012, over 1 million total joint arthroplasties were performed in the US with the cost of US$ 18.8 bn. In 2010, each total knee arthroplasty revision surgery was associated with total costs of US$ 49,360. In addition, high unmet needs among patients are expected to challenge the growth of target market. There are currently inadequate treatment options as they focus primarily on the relief of symptoms and reduction of pain. No medications are available to cure reverse or prevent the progression of illness, such as arthritis. In addition, some patients cannot find relief with current medications and still experience pain, so in patients with joint pain, there are significant unmet needs. However, increasing investment by major players for R&D activities, high healthcare spending by the government of developing countries, and introduction of enhanced solutions are factors expected to create new opportunities for major players operating in the joint pain injections market over the forecast period.
Joint Pain Injections Market Segment Analysis, 2020
The global joint pain injections market is segmented into type, joint type, and distribution channel. The type segment is bifurcated into hyaluronic acid injections, corticosteroid injections, and others. Among type the corticosteroid injections generated revenue of US$ 2.5 Bn in 2020. Hyaluronic acid injections are mostly used for knee pain due to osteoarthritis. Such injections are administered if corticosteroids fail to relieve pain. Hyaluronic acid is identical to the material that lubricates the joints in the normal state of the body. The physicians aim to produce more lubrication in the joint, helping it function properly, by injecting more hyaluronic acid into the knee. In order to reduce side effects associated with non-steroidal anti-inflammatory drugs (NSAID) and corticosteroid treatments, the number of osteoarthritis patients finding potential knee replacement solutions has grown.
Players operating in the global joint pain injections market are Allergan Plc., Pfizer Inc., Ferring B.V., Flexion Therapeutics, Inc., Bioventus, Zimmer Biomet Holdings, Inc., Sanofi, Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, and Chugai Pharmaceutical Co., Ltd. The market competition is high due to the large presence of players operating in the market. Enterprises are under high pressure to deliver better quality products and increase the customer base. Activities such as business acquisitions and new partnerships are expected to help the company enhance its business and increase its revenue share.
Market by Type:
Market by Joint Type:
Market by Distribution Channel:
Market By Geography
Market in 2028 is expected to be above US$ 10.3 Bn and CAGR from 2021-2028 is above 8.2%
Prominent players operating in the target market are Allergan Plc., Pfizer Inc., Sanofi, Ferring B.V., and Flexion Therapeutics, Inc.
North America dominated and Asia Pacific region exhibited the fastest growing CAGR